lamotrigine has been researched along with Multiple Sclerosis in 17 studies
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this phase 2 trial, we aimed to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with secondary progressive multiple sclerosis." | 9.14 | Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. ( Altmann, DR; Brenner, R; Chataway, J; Furby, J; Hayton, T; Hughes, RA; Kapoor, R; Miller, DH; Smith, KJ, 2010) |
| " The 2 treatment periods began with an 8-week, double-blind titration period, during which the number of pills of study drug was increased until either total pain relief was achieved, 1 or more unmanageable adverse events were reported, or a maximum of 16 pills (400 mg of lamotrigine) were used daily." | 9.12 | A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. ( Breuer, B; Guleyupoglu, N; Knotkova, H; Pappagallo, M; Portenoy, RK; Wallenstein, S, 2007) |
| " In this phase 2 trial, we aimed to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with secondary progressive multiple sclerosis." | 5.14 | Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. ( Altmann, DR; Brenner, R; Chataway, J; Furby, J; Hayton, T; Hughes, RA; Kapoor, R; Miller, DH; Smith, KJ, 2010) |
| " The 2 treatment periods began with an 8-week, double-blind titration period, during which the number of pills of study drug was increased until either total pain relief was achieved, 1 or more unmanageable adverse events were reported, or a maximum of 16 pills (400 mg of lamotrigine) were used daily." | 5.12 | A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. ( Breuer, B; Guleyupoglu, N; Knotkova, H; Pappagallo, M; Portenoy, RK; Wallenstein, S, 2007) |
| "Lamotrigine displayed the lowest risk of discontinuation when prescribed as initial monotherapy for epilepsy in MS." | 4.02 | Retention of antiseizure medications for epilepsy in multiple sclerosis: A retrospective observational study. ( Burman, J; Håkansson, S; Mahamud, Z; Zelano, J, 2021) |
| "Treatment with lamotrigine was associated with more rashes (20% vs 5%, P value 0." | 2.52 | Sodium channel blockers for neuroprotection in multiple sclerosis. ( Hao, Z; Wen, J; Yang, C; Zeng, L; Zhang, L, 2015) |
| "Lamotrigine trial in SPMS was a randomised control trial to assess whether partial blockade of sodium channels has a neuroprotective effect." | 1.39 | Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression. ( Brenner, R; Furby, J; Giovannoni, G; Gnanapavan, S; Grant, D; Hayton, T; Kapoor, R; Leoni, V; Marta, M; Miller, DH; Morant, S; Palace, J; Teunissen, CE, 2013) |
| "Carbamazepine (CBZ) was prescribed in 36 patients, with adverse effects reported in 20 cases, of which 12 mimicked a relapse." | 1.33 | Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. ( Battaglia, MA; Brichetto, G; Mancardi, GL; Messmer Uccelli, M; Solaro, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Browne, L | 1 |
| Lidster, K | 1 |
| Al-Izki, S | 1 |
| Clutterbuck, L | 1 |
| Posada, C | 1 |
| Chan, AW | 1 |
| Riddall, D | 1 |
| Garthwaite, J | 1 |
| Baker, D | 1 |
| Selwood, DL | 1 |
| Mahamud, Z | 1 |
| Håkansson, S | 1 |
| Burman, J | 1 |
| Zelano, J | 1 |
| Gnanapavan, S | 1 |
| Grant, D | 1 |
| Morant, S | 1 |
| Furby, J | 2 |
| Hayton, T | 2 |
| Teunissen, CE | 1 |
| Leoni, V | 1 |
| Marta, M | 1 |
| Brenner, R | 2 |
| Palace, J | 1 |
| Miller, DH | 2 |
| Kapoor, R | 4 |
| Giovannoni, G | 1 |
| Yang, C | 1 |
| Hao, Z | 1 |
| Zhang, L | 1 |
| Zeng, L | 1 |
| Wen, J | 1 |
| Smith, KJ | 2 |
| Altmann, DR | 1 |
| Chataway, J | 1 |
| Hughes, RA | 1 |
| Bermel, RA | 1 |
| Cohen, JA | 1 |
| Valentino, P | 1 |
| Nisticò, R | 1 |
| Pirritano, D | 1 |
| Bilotti, G | 1 |
| Del Giudice, F | 1 |
| Sturniolo, M | 1 |
| Quattrone, A | 1 |
| Bittner, S | 1 |
| Höhn, K | 1 |
| Göbel, K | 1 |
| Kleinschnitz, C | 1 |
| Wiendl, H | 1 |
| Meuth, SG | 1 |
| Solaro, C | 3 |
| Brichetto, G | 1 |
| Battaglia, MA | 1 |
| Messmer Uccelli, M | 1 |
| Mancardi, GL | 3 |
| Reiss, JP | 1 |
| Sam, D | 1 |
| Sareen, J | 1 |
| Bechtold, DA | 1 |
| Miller, SJ | 1 |
| Dawson, AC | 1 |
| Sun, Y | 1 |
| Berry, D | 1 |
| Breuer, B | 1 |
| Pappagallo, M | 1 |
| Knotkova, H | 1 |
| Guleyupoglu, N | 1 |
| Wallenstein, S | 1 |
| Portenoy, RK | 1 |
| McCleane, G | 1 |
| Uccelli, MM | 1 |
| Cianchetti, C | 1 |
| Zuddas, A | 1 |
| Randazzo, AP | 1 |
| Perra, L | 1 |
| Marrosu, MG | 1 |
| Leandri, M | 1 |
| Lundardi, G | 1 |
| Inglese, M | 1 |
| Messmer-Uccelli, M | 1 |
| Gottlieb, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial[NCT02104661] | Phase 2 | 30 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis: Single Centre, Phase 2 Trial[NCT00257855] | Phase 2 | 120 participants | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for lamotrigine and Multiple Sclerosis
| Article | Year |
|---|---|
Sodium channel blockers for neuroprotection in multiple sclerosis.
Topics: Disease Progression; Female; Humans; Immunosuppressive Agents; Lamotrigine; Male; Middle Aged; Multi | 2015 |
[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications].
Topics: Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Antineoplastic Agents; Carbamazepine; Cohor | 2011 |
Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine.
Topics: Animals; Humans; Lamotrigine; Multiple Sclerosis; Neuroprotective Agents; Sodium Channel Blockers; T | 2008 |
3 trials available for lamotrigine and Multiple Sclerosis
| Article | Year |
|---|---|
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method | 2010 |
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method | 2010 |
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method | 2010 |
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Topics: Adolescent; Adult; Brain Infarction; Disability Evaluation; Disease Progression; Double-Blind Method | 2010 |
A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis.
Topics: Anticonvulsants; Cross-Over Studies; Double-Blind Method; Female; Humans; Lamotrigine; Male; Middle | 2007 |
Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis.
Topics: Analgesics; Analgesics, Non-Narcotic; Carbamazepine; Female; Humans; Lamotrigine; Male; Middle Aged; | 2000 |
11 other studies available for lamotrigine and Multiple Sclerosis
| Article | Year |
|---|---|
Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis.
Topics: Animals; Disease Models, Animal; Female; Humans; Imidazoles; Lymph Nodes; Male; Mice; Mice, Inbred C | 2014 |
Retention of antiseizure medications for epilepsy in multiple sclerosis: A retrospective observational study.
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Multiple Sclerosis; Sweden | 2021 |
Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.
Topics: Atrophy; Biomarkers; Brain; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; | 2013 |
Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options.
Topics: Adjuvants, Immunologic; Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2011 |
Lamotrigine therapy for paroxysmal dysarthria caused by multiple sclerosis: a case report.
Topics: Adult; Anticonvulsants; Ataxia; Dysarthria; Female; Humans; Lamotrigine; Magnetic Resonance Imaging; | 2011 |
Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study.
Topics: Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Follow-Up Studies; | 2005 |
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delusions; Excitatory Amino Acid Antagonists; Female; | 2006 |
Axonal protection achieved in a model of multiple sclerosis using lamotrigine.
Topics: Action Potentials; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Lamotrigine; M | 2006 |
Lamotrigine can reduce neurogenic pain associated with multiple sclerosis.
Topics: Adult; Analgesics; Female; Humans; Lamotrigine; Multiple Sclerosis; Pain; Triazines | 1998 |
A patient with multiple sclerosis and Down's syndrome with a rare paroxysmal symptom at onset.
Topics: Acetates; Amines; Brain; Cyclohexanecarboxylic Acids; Down Syndrome; Excitatory Amino Acid Antagonis | 1999 |
Lamotrigine adjunctive therapy in painful phenomena in MS: preliminary observations.
Topics: Analgesics; Female; Humans; Lamotrigine; Male; Multiple Sclerosis; Pain; Triazines | 1999 |